about
Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patientsDendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Will post-transplantation cell therapies for pediatric patients become standard of care?Multi-institutional assessments of transplantation for metabolic disordersAdvances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disordersAntitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentationA novel Dutch mutation in UNC13D reveals an essential role of the C2B domain in munc13-4 functionDifferent NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicityEnhanced susceptibility to subcutaneous abscess formation and persistent infection around catheters is associated with sustained interleukin-1beta levelsEnzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantationEarly Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III.Metachromatic leukodystrophy: Disease spectrum and approaches for treatment.Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.The clinical outcome of Hurler syndrome after stem cell transplantation.Functional and genetic characterization of two extremely rare cases of Williams-Beuren syndrome associated with chronic granulomatous disease.Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation.Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.Musculoskeletal manifestations of lysosomal storage disorders.Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders.How I treat adenovirus in hematopoietic stem cell transplant recipientsDoes high-resolution CT has diagnostic value in patients presenting with respiratory symptoms after hematopoietic stem cell transplantation?Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.Changing winds in refractory autoimmune disease in children: clearing the road for tolerance with cellular therapies.Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation.Stem cell comparison: what can we learn clinically from unrelated cord blood transplantation as an alternative stem cell source?Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children.Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients.Neurodevelopmental Outcome after Hematopoietic Cell Transplantation in Inborn Errors of Metabolism: Current Considerations and Future Perspectives.Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy.Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.Transplantation in inborn errors of metabolism: current considerations and future perspectives.
P50
Q24684113-A79CCAA3-193E-4DC6-90E9-285AB084D5D8Q26830857-37D3E7D6-AD26-414A-B601-7D55165E6F80Q27008318-DA244D0D-EC8C-45E0-AC8E-A81DC655C2E2Q27012556-885B724E-B9BA-466A-A15D-CA2193F43850Q27022561-EA97C277-D2DC-48B3-9299-57F5D5F20DA0Q27026193-E31D6FC7-9832-4B3B-9503-8E6E336AA386Q28243216-90A142EC-87C2-4001-AF66-4CD2B6EBFE1EQ28256255-D4467C59-A6B2-4B34-B46E-7C64E2FF2FC2Q34003710-45A8DCE7-BC01-48FC-8ED1-407922E9F1ADQ34207169-0AAB5B59-6492-416E-BB8A-353A00A9EFECQ34333060-B67A05B5-750F-48D4-A3F8-E45A8B89C82FQ34356914-CCEA3AEB-9CA8-4D39-BD17-AB2573B9CCA3Q34393200-7633BAA2-74FA-4636-ADE6-FE31574BC873Q34991001-B2364C24-563D-4A48-B86E-26BADAB10141Q35183102-ECD2D30C-5F75-4B2C-8E62-538AF9BE47B2Q35634674-279C0741-0A4F-4C85-BD4E-39F4DB5F2803Q36107961-F8C07378-754A-4CAC-82F4-F62BAEEFF17AQ36505462-BBCC61AD-C2F5-4BB6-A80A-2E060B0EFFC9Q36812193-81C80EAD-3142-4AB2-BCE5-CC08320F0153Q37138145-DD2E1156-1BFC-461B-8897-5B9C7D71E777Q37186009-9C68F22D-9F35-4608-927D-C14120398CE4Q37284194-F9784F7A-4FFF-4010-863C-570FA3E328B5Q37358921-8F13D20E-D968-4F10-9695-2548789DEC5DQ37613315-A7D9543A-1086-4F1B-9FB7-F78CE66D0AD1Q37716127-CAD3A26C-FF38-4BCF-9A33-72811736606DQ37788461-7FF7C9A8-9639-4D64-93FB-5F34FCDCE651Q37835510-4E32454F-F292-47A1-BB77-48CE6CE50317Q37874330-23D2E746-E889-40D3-BFFD-A25C660AB5FAQ37988027-DF8DCB3D-AC6E-4D75-A8DB-4D348C51E4FFQ37993744-29FE82CF-1AB2-4078-A1F1-98DC69AF9FD6Q38262786-627D353B-CFA0-41F0-B76A-81A7B9502900Q38284507-FC7C6243-111E-40E7-B4FA-36A83332E198Q38385963-B2C7FA13-D039-49EA-BD06-A83FBB60F400Q38423263-77FFC994-6702-4ACD-81BE-AD413A5FEBA3Q38581051-BDF69BFD-37A4-487E-A0A9-34FE518CC417Q38641112-1C8F3CAA-8190-4E7C-BCED-0DB893A2DA18Q38852392-D37982F4-CE46-4F00-A979-FF813E486F52Q38897538-2F87F630-F46D-4547-8A8D-A994F728C49AQ39049336-E4CA60DB-88BE-4FED-B2C7-42B31CB7BBA7Q39151620-CB6B226A-DC75-43D9-83F7-C6F2C754D0A1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jaap J. Boelens
@ast
Jaap J. Boelens
@en
Jaap J. Boelens
@es
Jaap J. Boelens
@nl
Jaap J. Boelens
@sl
type
label
Jaap J. Boelens
@ast
Jaap J. Boelens
@en
Jaap J. Boelens
@es
Jaap J. Boelens
@nl
Jaap J. Boelens
@sl
prefLabel
Jaap J. Boelens
@ast
Jaap J. Boelens
@en
Jaap J. Boelens
@es
Jaap J. Boelens
@nl
Jaap J. Boelens
@sl
P106
P1153
14014030800
P21
P31
P496
0000-0003-2232-6952